Dr. Borgen Discusses HER2 Blockade in Breast Cancer

Video

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses HER2 blockade in the treatment of patients with HER2-positive breast cancer.

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses HER2 blockade in the treatment of patients with HER2-positive breast cancer.

One of the questions that comes up with HER2-positive breast cancers, is at what tumor size in the node-negative setting should HER2 blockade be considered? Borgen says that for small tumors that are otherwise favorable, patients should receive a taxane and trastuzumab (Herceptin), based on the survival rate from the APT trial in patients with early-stage breast cancers that were HER2-positive. These are patients who are not going to need multimodal cytotoxic therapy or targeting of HER2, as this adjuvant regimen induced a 97% 5-year disease-free survival in the APT trial.

For patients with tumors that are 5 mm, HER2 blockade might be considered. For patients with tumors that exceed 6 mm, HER2 blockade should absolutely be used, Borgen says.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD